The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...

Aloft Bangkok-Sukhumvit 11, the first Aloft hotel in Thailand and part of Marriott Bonvoy's portfolio of over 30 ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

Copenhagen Infrastructure Partners and Friesen Elektra Green Energy AG have launched project Anker, a green hydrogen production facility in Sande, Lower Saxony, Germany COPENHAGEN, Denmark , Jan. 15, ...

The European Medicines Agency is reviewing AVT03, a proposed biosimilar to Prolia and Xgeva, as well as AVT05, a proposed biosimilar to Simponi. The company started generating product revenue in ...

Alvotech and Teva announce filing acceptance of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab) Latest news ...

Alvotech and Teva announce filing acceptance of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab) Latest news ...